Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphoma

Lars Kurch1*, Ulrich Dührsen2, Andreas Hüttmann2, Thomas W. Georgi1, Osama Sabri1, Regine Kluge1 and Dirk Hasenclever3

Abstract
Background: Interim [18F]fluoro-deoxyglucose-positron emission tomography predicts outcome in peripheral T-cell lymphoma (PTCL). We compared two quantitative evaluation methods.

Methods: Interim scans from 43 patients with anaplastic lymphoma kinase-negative PTCL from the ‘Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas’ trial were re-analyzed by qPET (relating residual lymphoma-related uptake to liver uptake) and ∆SUVmax (relating interim scan to baseline scan). The endpoint was progression-free survival.

Results: qPET and ∆SUVmax were closely correlated (Pearson’s \( r = 0.627 \)). Up to the 60th percentile of values ranked by increasing residual activity, the positive predictive value for progression or death increased from 60 to 95%, with stable negative predictive values (NPV) of 60%. Beyond the 60th percentile, the NPV decreased to 40%. qPET \( \geq 2 \) and ∆SUVmax < 50% identified high-risk populations comprising 41.9% and 39.5% of patients, with 3-year progression-free survival rates of 5.6% (95% confidence interval, 0.8–37.3) and 0%, respectively, as compared to 63.7% (47.4–85.8) and 61.3% (45.1–83.3) in low-risk patients.

Conclusions: qPET and ∆SUVmax identify large fractions of PTCL patients destined to experience treatment failure. qPET may be preferred because it requires a single PET scan, halving the diagnostic effort.

Keywords: Peripheral T-cell lymphoma, Positron emission tomography, Interim evaluation, Deauville scale, ∆SUVmax, qPET

Introduction
Peripheral T-cell lymphoma (PTCL) is a rare disease in Europe and North America, with a yearly incidence of less than 1 in 100,000. It encompasses several entities, which are mainly of aggressive behavior. Response to chemotherapy is generally poor, with long-term survival rates of 30% [1]. Early identification of impending treatment failure may improve outcome.

In a subgroup analysis of the ‘Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas’ (PETAL) trial [2] we showed that interim [18F]fluoro-deoxyglucose-positron emission tomography/computed tomography ([18F]-FDG-PET/CT) predicts outcome in all major PTCL subtypes except anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) which has a much better prognosis than the other entities [3]. The ∆SUVmax method, comparing the maximum standardized uptake values (SUVmax) at baseline and interim scanning, appeared better suited than the interim PET-based Deauville 5-point scale with a threshold at score 4 (residual...
lymphoma-related activity above liver) to predict treatment failure. Score 5 (residual activity markedly above liver) performed better, but its imprecise definition hampers clinical use [4].

To overcome the limitations of visual assessment, we employed qPET (q, quantitative) that relates the SUV of the most intense residual lymphoma-related lesion to the mean SUV of the liver. This procedure, pioneered in pediatric [5] and adult Hodgkin’s lymphoma [6] and confirmed in DLBCL [7], transforms the ordinal Deauville scale into a continuous scale with clearly defined borders between response categories. In this report, we apply qPET to the PTCL population of the PETAL trial and compare it with ∆SUVmax.

Patients and methods

Study design

The PETAL trial (ClinicalTrials.gov NCT005554164; EudraCT 2006-001641-33) was a multicenter study for newly diagnosed aggressive non-Hodgkin lymphomas [2]. The study was approved by the Federal Institute for Drugs and Medical Devices and the ethics committees of all participating sites. All patients gave written informed consent.

PTCL patients were treated with bi-weekly CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), with a 3-week interval between cycles 2 and 3 to prevent false-positive results at interim staging uniformly performed after cycle 2. Patients with favorable interim [18F]-FDG-PET response received four more cycles of CHOP. Patients with unfavorable response were randomly assigned to receive six additional cycles of CHOP or a more intensive protocol [2]. Because the modifications failed to change outcome [2], all treatment arms were combined in the present analysis. High-dose chemotherapy with autologous blood stem cell transplantation was reserved for relapse (n = 5), and allogeneic transplantation for second relapse (n = 1).

PET/CT imaging and evaluation

Scanning conditions and image analysis have been described previously [2, 7]. Archived baseline and interim [18F]-FDG-PET/CT images were re-analyzed by a single experienced physician (> 5000 evaluated lymphoma scans).

qPET was calculated by dividing the SUVpeak of the hottest residual lesion on the interim scan by the SUVmean of the liver. Both parameters were measured semiautomatically using a software tool developed in cooperation with Hermes Medical Solutions AB, Sweden. To determine the SUVpeak, a volume of interest (VOI) was drawn around the residual. Within this VOI the software automatically identified the maximum SUV voxel and the three hottest adjacent voxels which were used to calculate the mean SUV (SUVpeak). The SUVmean of physiological liver uptake was measured using a cuboid VOI of 30 ml (edge length proportion length:width:height = 2:2:1) which was placed in the right liver lobe (normally 7th/8th segment) [5]. Based on our previous results [5–7], qPET was used to define quantitative thresholds between the Deauville scores (qDS).

∆SUVmax was determined by dividing the SUVmax of the hottest residual lesion on the interim scan by the SUVmax of the hottest lesion on the baseline scan [2]. High risk of treatment failure was defined as SUVmax reduction < 50% [3].

Statistical analysis

The study endpoint was progression-free survival (PFS) defined as time from interim [18F]-FDG-PET scanning to disease progression, relapse, or death from any cause. For simplicity, we treated PFS as a binary variable (i.e. whether or not events occurred within 60 month). This appeared justified, because, in PTCL, the majority of events occur within the first two years [8], and, with a median follow-up of 52 months, the data were mature [2, 3].

We plotted empirical cumulative distribution functions (ECDFs) of qPET and used the area under the Receiver Operating Characteristic (ROC) curve to compare qPET and ∆SUVmax. Instead of ∆SUVmax, we used 1-∆SUVmax, i.e. the remaining proportion of [18F]-FDG uptake, which allowed us to use the log scale (no negative values) and rendered the correlation with qPET positive [7]. All analyses were carried out in R, version 3.5.1 (R Core Team, Vienna, Austria).

Results

Patients characteristics

Of 862 patients treated in the PETAL trial, 76 had PTCL [2]. Baseline and interim scans for post-hoc analyses were available from 57 patients (Additional file 1: Fig. S1). Baseline characteristics of included and excluded patients were similar. Forty-three patients had one of several types of ALK-negative PTCL, and 14 had ALK-positive ALCL (Table 1).

Response assessment

The ECDFs of SUV findings at interim scanning did not significantly differ between individual entities (Additional file 1: Fig. S2). At interim scanning, residual lymphoma-related activity was measurable in 32 ALK-negative PTCL and nine ALK-positive ALCL. The remaining patients’ scans were devoid of unphysiological activity. qPET and ∆SUVmax measurements were closely correlated (Pearson’s r = 0.627; 95% confidence interval [CI] 0.396–0.784)
and in line with the observations made in DLBCL (Fig. 1). In PTCL, interim qPET showed a moderate correlation with baseline SUV\textsubscript{max} (Pearson’s $r = 0.358$; 95% CI 0.057–0.600). No such correlation was seen in DLBCL (Fig. 2).

**Outcome prediction**

PFS was statistically significantly associated with PTCL subtype, with 3-year PFS rates of 38.9% in ALK-negative PTCL and 85.1% in ALK-positive ALCL (Additional file 1: Fig. S3). Since interim PET had failed to predict outcome of ALK-positive ALCL in our previous study [3], we restricted the comparison of qPET and ∆SUV\textsubscript{max} to ALK-negative PTCL. As judged by ROC analysis, both methods predicted PFS equally well, with almost identical areas under the curve (qPET, 0.775, 95% CI 0.631–0.92; ∆SUV\textsubscript{max}, 0.792, 95% CI 0.66–0.923; $p = 0.731$).

To compare the positive and negative predictive values of qPET and ∆SUV\textsubscript{max} at comparable thresholds, the values were plotted along their respective percentiles. This resulted in largely superimposable curves (Fig. 3). Up to the 60th percentile, the positive predictive value continuously increased from 60 to 95%, while the negative predictive value remained stable at 60%. Beyond the 60\textsuperscript{th} percentile, the negative predictive value decreased to 40%. Figure 3 also shows the positions of the qPET thresholds of 1.3 discriminating qDS3 and qDS4, and 2.0 discriminating qDS4 and qDS5 [5–7], and the 50% ∆SUV\textsubscript{max} threshold splitting the PTCL population in two prognostic groups [3].

---

### Table 1  Baseline characteristics of T-cell lymphoma patients

|                      | ALK-neg. peripheral T-cell lymphomas | ALK-pos. anaplastic large cell lymphoma |
|----------------------|--------------------------------------|-----------------------------------------|
|                      | Included | Excluded | Included | Excluded |
| No. of patients      | 43       | 12       | 14       | 7        |
| Peripheral T-cell lymphoma, not otherwise specified | 15       | 5        | n.a      | n.a      |
| Angioimmunoblastic T-cell lymphoma | 13       | 5        | n.a      | n.a      |
| ALK-negative anaplastic large cell lymphoma | 12       | 1        | n.a      | n.a      |
| Unclassified T-cell lymphoma | 3        | 1        | n.a      | n.a      |
| Age – median (range), years | 61 (26–77) | 70 (29–79) | 34 (20–66) | 32 (19–54) |
| Male sex             | 30 (70%) | 9 (75%)  | 9 (64%)  | 7 (100%) |
| ECOG performance status ≥ 2 | 3 (7%)  | 1 (8%)   | 0 (0%)   | 1 (14%)  |
| Ann Arbor stage III or IV | 30 (70%) | 8 (67%)  | 5 (36%)  | 5 (71%)  |
| Extramedial sites > 1 | 10 (23%) | 1 (8%)   | 2 (14%)  | 0 (0%)   |
| Lactate dehydrogenase > ULN | 25 (58%) | 7 (58%)  | 3 (21%)  | 1 (14%)  |

**International Prognostic Index**

|                      | Low risk | Low-intermediate risk | High-intermediate risk | High risk |
|----------------------|----------|-----------------------|------------------------|-----------|
|                       | 16 (37%) | 9 (21%)               | 12 (28%)               | 6 (14%)   |
|                       | 2 (17%)  | 6 (50%)               | 3 (25%)                | 1 (8%)    |
|                       | 11 (79%) | 3 (21%)               | 0 (0%)                 | 0 (0%)    |
|                       | 5 (71%)  | 2 (29%)               | 0 (0%)                 | 0 (0%)    |

ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of normal.

---

**Outcome according to prognostic group**

qDS5 (qPET ≥ 2) identified a high-risk group comprising 18 patients (41.9%), with a 3-year PFS rate of 5.6% (95% CI 0.8–37.3). By contrast, qDS1-4 was associated with a 3-year PFS rate of 63.7% (47.4–85.8), with similar rates (71.6% and 57.1%, respectively) for qDS1 (qPET = 0; $n = 11$) and qDS2-4 (qPET > 0 to < 2; $n = 14$). An SUV\textsubscript{max} reduction < 50% was seen in 17 patients (39.5%), with a 3-year PFS rate of 0%, compared to 61.3% (45.1–83.3) in patients with an SUV\textsubscript{max} reduction ≥ 50% (Fig. 4). Similar results were obtained for overall survival (Additional file 1: Fig. S4).

Multivariable analysis including interim $^{[18]}$F-FDG-PET response and International Prognostic Index (IPI) risk group was hampered by small patient numbers. Irrespective of IPI risk, poor interim $^{[18]}$F-FDG-PET response appeared to be associated with dismal outcome. Whether IPI had an impact on outcome of patients with good interim $^{[18]}$F-FDG-PET response, remained questionable (Additional file 1: Fig. S5).

**Discussion**

In the present study, interim $^{[18]}$F-FDG-PET evaluation by qPET and ∆SUV\textsubscript{max} yielded closely related measurements. Outcome prediction was similar, suggesting that the two methods convey comparable information. Importantly and in contrast to the visual Deauville scale, qPET clearly defines DS5, which is crucial for the identification of PTCL patients at high risk of treatment failure.
Fig. 1 Scatterplot of qPET and ΔSUV\textsubscript{max} values in peripheral T-cell lymphoma alone (top) and peripheral T-cell-lymphoma (filled blue circles) and diffuse large B-cell lymphoma (open black circles) combined (bottom). The data for diffuse large B-cell lymphoma have been published before [7]. CI, confidence interval; Nvalid, measurable residual activity.
Fig. 2 Scatterplot of qPET and baseline $\text{SUV}_{\text{max}}$ values in peripheral T-cell lymphoma (top) and diffuse large B-cell lymphoma (bottom). CI, confidence interval; $N_{\text{valid}}$, measurable residual activity.
Fig. 3 Positive predictive value (top) and negative predictive value (bottom) of corresponding percentiles of qPET and ΔSUV\text{max} measurements. The constant part of the curves at low percentiles is due to the inclusion of non-measurable values set at zero (n = 16).
Fig. 4 Progression-free survival in prognostic subgroups derived from the quantitative Deauville scale (top) and the ΔSUV\textsubscript{max} scale (bottom) (Kaplan-Meier analysis). qPET $< 2$ corresponds to quantitative Deauville score 1–4 (qDS1–4) and qPET $\geq 2$ corresponds to qDS5. CI, confidence interval.
The correlation between qPET and $\Delta$SUV$_{\text{max}}$ was similar to the findings in DLBCL [7]. qPET was correlated with baseline SUV$_{\text{max}}$ in PTCL, but not in DLBCL, reflecting differences in the responsiveness to chemotherapy. In most DLBCL patients, response is rapid and accompanied by a marked reduction in [$^{18}$F]-FDG uptake. In PTCL, chemotherapy is much less effective. Persistently high [$^{18}$F]-FDG uptake translates into high qPET values.

The large sample size (449–898 patients) of our previous qPET studies allowed us to define precise borders between the five Deauville categories [5–7]. Irrespective of disease, the borders identified were identical. Because the relationship between the uptake in a residual lesion and the reference region, as perceived by the reader, should not be disease-specific, we adopted the previously defined quantitative Deauville scale also for PTCL. The small size of our PTCL study precluded a formal confirmation of the thresholds.

Interim assessment in ALK-negative PTCL was characterized by higher positive and lower negative predictive values than in DLBCL [7], reflecting differences in the frequency of treatment failure [2]. qDS5 identified 18 of 43 patients (41.9%) to be at risk of treatment failure, all but one of whom progressed or died within 30 months. An SUV$_{\text{max}}$ reduction < 50% allocated 17 patients (39.5%) to the high-risk group, with similarly poor outcome. Both quantitative methods appear suitable to select patients for an early treatment change. qPET may be preferable, because it does not require a baseline [$^{18}$F]-FDG-PET/CT, thus minimizing the influence of factors interfering with the evaluation [7]. However, it is important to mention that the qPET method as described here was developed 10 years ago, based on scanner systems available at that time. With the new PET scanner generations voxel size became markedly smaller so that an adapted qPET calculation is recommendable which is independent of voxel size. In the EuroNet-PHL-C2 and the GPOH-HD2020 registry trials, the SUV$_{\text{peak}}$ is calculated as the SUV$_{\text{mean}}$ of the hottest connected voxels forming a volume of 0.2 ml (instead of the SUV$_{\text{mean}}$ of the 4 hottest voxels) [9].

For patients failing conventional chemotherapy, the most promising treatment is allogeneic transplantation. In a recent first-line trial, transplantation after five treatment cycles proved impossible in almost a third of patients, mainly because of progression beyond cycle 2 [10]. The window for allogeneic transplantation may be narrow in high-risk PTCL. Interim [$^{18}$F]-FDG-PET could help detect impending progression before it is too late.

The major limitation of our study is its small size, inherent in all investigations in rare diseases. The results should be confirmed in an independent cohort, preferably of larger size.

In conclusion, qPET requiring a single [$^{18}$F]-FDG-PET scan identifies similarly large fractions of PTCL patients at risk of treatment failure as does $\Delta$SUV$_{\text{max}}$ relying on a comparison of two scans. qPET stringently defines DS5 which is crucial for risk allocation.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13550-021-00827-1.

Additional file 1. Supplemental Figure 1. Patient selection according to the availability and evaluability of metabolic imaging data. Preconditions for study inclusion were the availability of [$^{18}$F]-FDG-PET images at staging and following two courses of CHOP chemotherapy on the central data server, including the opportunity to reliably perform quantitative measurements, i.e. $\Delta$SUV$_{\text{max}}$ and qPET calculations. Supplemental Figure 2. Empirical cumulative distribution functions of qPET (top) and $\Delta$SUV$_{\text{max}}$ values (bottom) from interim positron emission tomography for different peripheral T-cell lymphomas. PTCL peripheral T-cell lymphoma; NOS, not otherwise specified; ATLL, angioimmunoblastic T-cell lymphoma; ALK+ ALC, anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma; ALK- ALC, ALK-negative ALC. Supplemental Figure 3. Progression-free survival in anaplastic lymphoma kinase (ALK)-negative peripheral T-cell lymphomas (ALK- PTCL), ALK-positive anaplastic large cell lymphoma (ALK+ ALC), and diffuse large B-cell lymphoma (DLBCL). The DLBCL data have been published before [7]. CI, confidence interval. Supplemental Figure 4. Overall survival in prognostic subgroups derived from the quantitative Deauville scale (top) and the $\Delta$SUV$_{\text{max}}$ scale (bottom) (Kaplan-Meier analysis). qPET<2 corresponds to quantitative Deauville score 1–4 (qDS1–4) and qPET≥2 corresponds to qDS5. CI, confidence interval. Supplemental Figure 5. Progression-free survival in prognostic subgroups derived from the International Prognostic Index (score 0–2 versus 3–5) combined with the interim positron emission tomography response as assessed by the quantitative Deauville scale (top) or the DSUV$_{\text{max}}$ scale (bottom) (Kaplan-Meier analysis).

Authors’ contributions

1. Conception and Design: LK, DH, UD, 2. Data Acquisition: LK, UD, AH. 3. Data Analysis: DH, LK, UD, RK, TWG. 4. Data Interpretation: DH, LK, UD, AH, TWG, OS, RK, 5. Visualization: DH, LK, UD, 6. Drafting: UD, DH, LK, AH, TWG, OS, RK, 7. Revision: UD, LK, DH, AH, TWG, OS, RK. 8. Final Approval and Agreement of accountability for all aspects of the work: UD, LK, DH, AH, TWG, OS, RK.

Funding

Open Access funding enabled and organized by Projekt DEAL. This work is based on a study funded by Deutsche Krebshilfe (Grant Nos. 107592 and 110515), Amgen Germany, and Roche Pharma. The pharmaceutical companies had no role in study design, data analysis, data interpretation, or writing of the manuscript.

Availability of data and materials

The datasets generated and analyzed are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate

The PETAL trial (ClinicalTrials.gov NCT00554164; EudraCT 2006-001641-33) was a multicenter study for newly diagnosed aggressive non-Hodgkin lymphomas. The study was approved by the Federal Institute for Drugs and Medical Devices and the ethics committees of all participating sites. All patients gave written informed consent including their permission to use their data for post-hoc scientific analyses.
**Competing interests**

UD received institutional research grants and honoraria from Amgen Germany and Roche Pharma. No other potential conflicts of interest relevant to this article exist.

**Author details**

1. Klinik Und Poliklinik Für Nuklearmedizin, Universitätsklinikum Leipzig, Leipzig, Germany.
2. Klinik Für Hämatologie, Universitätsklinikum Essen, Essen, Germany.
3. Institut Für Medizinische Informatik, Statistik Und Epidemiologie, Universität Leipzig, Leipzig, Germany.

Received: 17 June 2021  Accepted: 17 August 2021

Published online: 14 September 2021

**References**

1. Ellin F, Landström J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014. https://doi.org/10.1182/blood-2014-04-573089.

2. Dührsen U, Müller S, Hertenstein B, et al. Positron emission tomography-guided therapy of aggressive non-hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol. 2018. https://doi.org/10.1200/JCO.2017.76.8093.

3. Schmitz C, Rekowski J, Müller SP, et al. Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: a subgroup analysis of the PETAL trial. Hematol Oncol. 2020. https://doi.org/10.1002/hon.2697.

4. Barrington SF, Mikhaeil NG, Kostakoglou L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014. https://doi.org/10.1200/JCO.2013.53.5229.

5. Hasenclever D, Kurch L, Mauz-Körholz C, et al. qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma. Eur J Nucl Med Mol Imaging. 2014. https://doi.org/10.1007/s00259-014-2715-9.

6. Georgi TW, Kurch L, Hasenclever D, et al. Quantitative assessment of interim PET in Hodgkin lymphoma: an evaluation of the qPET method in adult patients in the RAPID trial. PLoS ONE. 2020. https://doi.org/10.1371/journal.pone.0231027.

7. Kurch L, Andreas H, Georgi TW, et al. Interim positron emission tomography in diffuse large B-cell lymphoma. J Nucl Med. 2020. https://doi.org/10.2967/jnumed.120.255034.

8. Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017. https://doi.org/10.1200/JCO.2017.73.8195.

9. Kluge R, Wittig T, Georgi TW, et al. Comparison of interim PET response to second-line versus first-line treatment in classic Hodgkin lymphoma: contribution to the development of response criteria for relapsed or progressive disease. J Nucl Med. 2021. https://doi.org/10.2967/jnumed.120.247924.

10. Schmitz N, Truemper LH, Bouabdallah K, et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2021;137:2646. https://doi.org/10.1182/blood.2020008825.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.